

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BECKMANN et al

Serial No. 08/836,734

Filed: July 2, 1997

Title: LGMD GENE CODING FOR A CALCIUM DEPENDENT PROTEASE


Atty Dkt. 960-29

C# M#

Group Art Unit: 1634

Examiner: Zitomer, S.

Date: August 30, 2001



RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
BOX 560
AUG 30 2001
TECH CENTER 1600/2900
SERIAL NO. 3/04/2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO NOTICE TO COMPLY

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

| | | | | |
|--|----|----------------------|---|------------|
| Total effective claims after amendment | 0 | minus highest number | | |
| previously paid for | 20 | (at least 20) = | 0 | x \$ 18.00 |
| | | | | \$ 0.00 |

| | | | | |
|------------------------------------|---|----------------------|---|------------|
| Independent claims after amendment | 0 | minus highest number | | |
| previously paid for | 3 | (at least 3) = | 0 | x \$ 80.00 |
| | | | | \$ 0.00 |

| | | | | |
|--|--|--|--|---------|
| If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) | | | | \$ 0.00 |
|--|--|--|--|---------|

| | | | | |
|--|--|--|--|-----------|
| Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) | | | | \$ 890.00 |
|--|--|--|--|-----------|

| | | | | |
|---|--|--|--|---------|
| Terminal disclaimer enclosed, add \$ 110.00 | | | | \$ 0.00 |
|---|--|--|--|---------|

| | | | | |
|---|--|--|--|---------|
| <input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) | | | | \$ 0.00 |
| <input type="checkbox"/> Please enter the previously unentered , filed | | | | |
| <input type="checkbox"/> Submission attached | | | | |

| | | |
|-----------------|----|---------------|
| Subtotal | \$ | 890.00 |
|-----------------|----|---------------|

| | | | | |
|---|---|--|--|-----------|
| If "small entity," then enter half (1/2) of subtotal and subtract | | | | \$ 445.00 |
| <input type="checkbox"/> Applicant claims "small entity" status. | <input type="checkbox"/> Statement filed herewith | | | |

| | | | | |
|--|--|--|--|---------|
| Rule 56 Information Disclosure Statement Filing Fee (\$180.00) | | | | \$ 0.00 |
|--|--|--|--|---------|

| | | | | |
|------------------------------------|--|--|--|---------|
| Assignment Recording Fee (\$40.00) | | | | \$ 0.00 |
|------------------------------------|--|--|--|---------|

| | | | | |
|--------|--|--|--|-------------|
| Other: | | | | 0.00 |
|--------|--|--|--|-------------|

| | | |
|---------------------------|----|---------------|
| TOTAL FEE ENCLOSED | \$ | 445.00 |
|---------------------------|----|---------------|

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

TECH CENTER 1600/2900

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
BOX 560
AUG 30 2001
TECH CENTER 1600/2900
SERIAL NO. 3/04/2001
DISK TO STIC
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
BOX 560
AUG 30 2001
TECH CENTER 1600/2900
SERIAL NO. 3/04/2001

SEP 04
2001
SEARCH CENTER
1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.



2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).



4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."



5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).



6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).



7. Other: SEQ ID NOS: for claimed Fig. 2A, 2C sequences
must be provided before case can be examined.

Applicant must provide:



An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"



An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification



A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.